ERBB2 and breast cancer: Compared to HER2+ breast cancer in the TCGA Caucasian cohort, we found TP53 (66.7% in FUSCC vs 41.0% in TCGA Caucasian, P = 0.001) with a higher frequency and GATA3 (5.0% in FUSCC vs 10.3% in TCGA Caucasian, P = 0.01) with a lower frequency in our cohort (Fig. 2g).